Mutants of Brucella melitensis
AssigneeThe United States of America as represented by the Secretary of the Army
InventorsHuo-shu H. Houng, Richard L. Warren
Life of this patent
Estimating the term…
Abstract
The vaccines are prepared by isolating the Brucella genes complementing mutations in the purEK genes of Escherichia coli, physically mapping, determining the DNA sequence, constructing a defined deletion mutation by polynucleotide chain reaction (PCR), introducing a selectable marker into the deletion, and then selecting a purE mutant in Brucella arising by allelic exchange. The resulting Brucella require purines for growth because they lack the purE gene product that is required for the carboxylation of 5'-phosphoribosyl-5-aminoimidazole.
Claims9
A recombinant E. coli containing an insert of a Brucella species coding region wherein the purE gene has been mutated, containing SEQUENCE ID NO 1, which is
- ______________________________________ GTGAGCGGAT AACAATTTCA CACAGGAAAC AGCTATGACC ATGATTACGC CAAGCTTCAG GAAATGGAAG ATCAGGTCAT TCCTGACATC ATTGCCTGAA CATTCAAGAA CACTATAGGG AAGAGCCGGG GTTCGCTGCT TGTCTTTTCA AGACCTTCCT CATGCCAACC GAAAAGCCAA GCAGGAAAGA CCGATGAGCG TTGATGTCGC CATTATCATG GGAAGCCAGT CCGATTGGGA AACCATGCAC CATGCAGCCG ACACATTGGA GGCGCTCGGC ATCTCCTTCG ACGCACGGAT CGTTTCCGCC CATCGCACCC CTGACAGGCT GGTCGCCTTC GCCAAGGGGG CGAAACGGGA AGGCTTCAAG GTCATCATCG CAGGCGCCGG CCGCGCCCAC CTGCCCGGCA TGGCCGCTGC CATGACACCG CTTCCCGTCT TTGGCGTTCC AGTTCAATCC AAGGCGCTTT CGGGCCAGGA TTCGCTACTC TCCATCGTAC AGATGCCAGC GGGTATTCCC GTCGGCACTC TCGCCATCGG CCGTGCAGGC GCGGTCAATG CCGCCCTTCT CGCCGCCGCC GTTCTGGCGC TATATGATGA AGCACTTGCC GCCCGTCTTG ATGAATGGCG CAAGGCGCAG ACCGAAAGCG TTGCAGAACG CCCCTCGAAC GAAGCCTGAT CCGGCGAGGT AGAAAATGGA CAAGACATCT CTCAAGCCCG GCTCCACCAT CGGCATTATC GGCGGGGGCC AGCTTGGCGT ATGCTCGCCA TGGCAGCGGC GCGCTTCGGT TATGAAACCA TAATCCTTGA GCCGCACGCG GTTGCCCGGC AGCACAGGTT GCCAATCGCC AGATTGTCGC CGCCTATGAT GACCCGAAGC GCTGGCCGAA ACTTGCCGCC GCTTCCGACG TCATCACCTA TGAATTTGAA AATGTGCCAG TCAGCGCCGC CGACAAGCTG GCTGAAACGG CGCTTGTTCT GCCCCCGCCC GCCGCACTGG AAATCTCTCA GGACCGCTTC ACAGAAAAGC AGTTTCTCAA CGAAAGCGGC ATTGAAACCG CGCCCTGGCG GCTCGTGGAT GACGAGGAAA CGCTCATCGC CGCGCTCGGC ACTTGGGCGG GCGTGGCATC CTCAAGATCG GCGTCTGGGT TATGACGGCA AGGGGCAGGT GCGCCTTGCC TCCCTCGATG AAACCCAGGC CTGCAACGCT TTTGCAGCCA TCAACAAGGC GCCTGCGATT CTCGAAGGCT TCGTGGAATT CGAGCGCGAA GTCTCCGTCA TCGCCGCGCG CGATCGCAGC GGCAATGTCG CCATCTTCGA TCTTGCGGAA AACGTCCACA AGGATGGCAT TCTCGCCACG TCCACAGTGC CTGCCGCGAT CAGCGTACAG ACGGCAGAAG CCGCGCGCAC AGCCGCCGAA AAACTGTTGC ACGCGCTGGA CTATGTCGGT GTGCTGGGGC TTGAATTCTT CGTGCTGAAG GACGGCACGC TGCTCGCCAA TGAATTTGCC CCGCGTGTGC ATAATTCGGG CCACTGGACG GAAGCAGCCT GCGCCATTTC CCAATTTGAG CAGCATATCC GCGCTGTGGC GGGACTGCCG CTCGGCAATA CGGATCGCCA TAGCGACTGT GTGATGGAAA ACCTGATTGG CGACGATATC GAAAAGGTTC CGGCGATTCT CTGCGAGAAG AACGCCGTGC TGCATCTTTA CGGTAAAAAG GAAGCTCGCG CGGGCCGGAA AATAGGCCAT GTGACCCGCA TAAAGCCCCG CACAATTTAA GCTGCGCCGG GAATCTGCAC GATTCCCGGC CCTTCCTGGC CGCCCGCCAA GAAATTCGGG GCCTCGGACC CTGAATCTGC GGCGCGGGAG TTGACATTTG CCTGAAACCT TGTGTATTTC GGCCAACTTC GGCACCTGAC. ______________________________________
A composition of matter containing an immunologically effective amount of Brucella having a purE mutation of SEQUENCE ID NO 1, said Brucella organism being in a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.